Pharma Journalist -

AbbVie has entered into a new collaboration with life sciences AI company Valkai to expand the use of artificial intelligence across selected areas of clinical development. The…
Read More...

Novo Nordisk has reported new real-world data suggesting that adults with type 2 diabetes who increased their once-weekly semaglutide injection dose from 1 mg to 2 mg had a lower risk…
Read More...

Novo Nordisk has entered into a licensing agreement with Hengrui Pharma for HRS-1596, a Phase 1-ready oral drug candidate that targets both GLP-1 and GIP receptors. Under the…
Read More...

AbbVie has received U.S. Food and Drug Administration (FDA) approval for JUVMO (tavapadon), a once-daily oral treatment for adults with Parkinson’s disease. The approval makes JUVMO the…
Read More...

Tolerance Bio has entered into an exclusive licensing agreement with Tanabe Pharma Corporation to develop and commercialize TLB-33, a clinical-stage anti-IL-33 monoclonal antibody,…
Read More...

While splice modulation has produced some of the field's most significant successes to date, researchers are increasingly exploring direct RNA binding as a route to achieving…
Read More...

Daiichi Sankyo and MSD have voluntarily withdrawn their U.S. Biologics License Application (BLA) for ifinatamab deruxtecan in adults with extensive-stage small cell lung cancer…
Read More...

TriSalus Life Sciences has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TriNav Advance, a new device designed to expand pressure-enabled drug delivery options…
Read More...

Turbine and Daiichi Sankyo have expanded their collaboration to use virtual biology and computational experiments to support the discovery and development of antibody-drug conjugates…
Read More...

Genialis and Inventia Life Science have announced a collaboration aimed at improving how new pancreatic cancer treatments are tested and matched to patients who may benefit from them.…
Read More...